NCT02573233 - Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 27, 2016

Primary Completion Date

January 3, 2018

Study Completion Date

January 3, 2018

Conditions

Asthma

Interventions

DRUG

Placebo

Pharmaceutical form:solution Route of administration: subcutaneous

DRUG

Dupilumab SAR231893/REGN668

Pharmaceutical form:solution Route of administration: subcutaneous

DRUG

fluticasone propionate and salmeterol

Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled

DRUG

budesonide and formoterol

Pharmaceutical form:inhalation aerosol Route of administration: inhaled

DRUG

mometasone furoate and formoterol

Pharmaceutical form:inhalation aerosol Route of administration: inhaled

Trial Locations (16)

2400

Investigational Site Number 208001, København NV

2650

Investigational Site Number 208002, Hvidovre

15213

Investigational Site Number 840028, Pittsburgh

22927

Investigational Site Number 276011, Großhansdorf

30625

Investigational Site Number 276012, Hanover

60596

Investigational Site Number 276013, Frankfurt am Main

63110

Investigational Site Number 840002, St Louis

80206

Investigational Site Number 840403, Denver

85724

Investigational Site Number 840402, Tucson

02115

Investigational Site Number 840401, Boston

27157-1071

Investigational Site Number 840404, Winston-Salem

H2X 2P4

Investigational Site Number 124012, Montreal

G1V 4G5

Investigational Site Number 124018, Sainte-Foy

221 85

Investigational Site Number 752001, Lund

W2 1NY

Investigational Site Number 826010, London

OX3 7LE

Investigational Site Number 826009, Oxford